Scorpion Therapeutics is an oncology company focused on transforming cancer treatment through an approach that offers precise selectivity and efficacy for oncology patients. Scorpion Therapeutics was founded in 2020 and is headquartered in Boston, MA. The company uses its proprietary technology platform that integrates cancer biology, medicinal chemistry, and data sciences for a holistic approach. The platform aims to allow Scorpion Therapeutics to create highly selective small-molecule compounds that target a broad spectrum of cancer drivers.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/16/2024 | Series C-1 | $125.69MM | $xx.xx | $821.83MM | Abingworth, Atlas Venture, Boxer Capital, Casdin Capital, Ecor1 Capital, Fidelity, Frazier Life Sciences, Invus, Lightspeed Venture Partners, Logos Capital, Nextech Invest, Omega Funds, Orbimed, Surveyor Capital, Vida Ventures, Wellington Management, Willett Advisors, Woodline Partners Lp | |
Price per Share
$xx.xx
Shares Outstanding
51,950,479
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth, Atlas Venture, Boxer Capital, Casdin Capital, Ecor1 Capital, Fidelity, Frazier Life Sciences, Invus, Lightspeed Venture Partners, Logos Capital, Nextech Invest, Omega Funds, Orbimed, Surveyor Capital, Vida Ventures, Wellington Management, Willett Advisors, Woodline Partners Lp
|
||||||
07/16/2024 | Series C-2 | $24.31MM | $xx.xx | $821.83MM | Abingworth, Atlas Venture, Boxer Capital, Casdin Capital, Ecor1 Capital, Fidelity, Frazier Life Sciences, Invus, Lightspeed Venture Partners, Logos Capital, Nextech Invest, Omega Funds, Orbimed, Surveyor Capital, Vida Ventures, Wellington Management, Willett Advisors, Woodline Partners Lp | |
Price per Share
$xx.xx
Shares Outstanding
9,579,780
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth, Atlas Venture, Boxer Capital, Casdin Capital, Ecor1 Capital, Fidelity, Frazier Life Sciences, Invus, Lightspeed Venture Partners, Logos Capital, Nextech Invest, Omega Funds, Orbimed, Surveyor Capital, Vida Ventures, Wellington Management, Willett Advisors, Woodline Partners Lp
|
||||||
01/07/2021 | Series B | $162MM | $xx.xx | $578.26MM | Abingworth & Partners Healthcare Innovation, Atlas Venture, Boxer Capital, Casdin Capital, Ecor1 Capital, Invus, Janus Henderson Investors, Logos Capital, Nextech Invest, Omega Funds, Orbimed, Surveyor Capital, Vida Ventures, Wellington Management, Woodline Partners Lp | |
Price per Share
$xx.xx
Shares Outstanding
66,957,944
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth & Partners Healthcare Innovation, Atlas Venture, Boxer Capital, Casdin Capital, Ecor1 Capital, Invus, Janus Henderson Investors, Logos Capital, Nextech Invest, Omega Funds, Orbimed, Surveyor Capital, Vida Ventures, Wellington Management, Woodline Partners Lp
|
||||||
10/26/2020 | Series A-1 | $52.84MM | $xx.xx | $191.3MM | Abingworth & Partners Healthcare Innovation, Atlas Venture, Omega Funds, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
52,837,500
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth & Partners Healthcare Innovation, Atlas Venture, Omega Funds, Vida Ventures
|
||||||
10/26/2020 | Series A-2 | $55.64MM | $xx.xx | $191.3MM | Abingworth & Partners Healthcare Innovation, Atlas Venture, Omega Funds, Vida Ventures | |
Price per Share
$xx.xx
Shares Outstanding
42,784,910
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abingworth & Partners Healthcare Innovation, Atlas Venture, Omega Funds, Vida Ventures
|